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Abstract
Introduction: Cancer cells secrete bioactive peptides that act in an autocrine or paracrine fashion
affecting tumor growth and metastasis. Corticotropin-releasing factor (CRF), a hypothalamic
neuropeptide that controls the response to stress, has been detected in breast cancer tissues and
cell lines. CRF can affect breast cancer cells in an autocrine or paracrine manner via its production
from innervating sympathetic neurons or immune cells.
Methods: In the present study we report our findings regarding the impact of CRF on breast
cancer cell motility and invasiveness. For this purpose we used the MCF7 breast cancer cell line
and evaluated the effect of CRF on motility and invasiveness using the wound-healing and boyden-
chamber assays. In addition, we measured the effect of CRF on molecules that mediate motility by
western blot, immunofluorescence, ELISA and RT-PCR.
Results: Our findings show that: 1. CRF transiently inhibited the apoptosis of MCF7 cells. 2. CRF
enhanced MCF7 cell motility in a wound healing assay and their invasiveness through extracellular
matrix. 3. CRF increased actin polymerization, phosphorylation of Focal Adhesion Kinase (FAK),
providing a potential mechanism for the observed induction of MCF7 motility. 4. CRF induced the
expression of Cox-1 but not Cox-2 in MCF7 cells as well as the production of prostaglandins,
factors known to promote invasiveness and metastasis.
Conclusion: Overall, our data suggest that CRF stimulates cell motility and invasiveness of MCF7
cells most probably via induction of FAK phosphorylation and actin filament reorganization and
production of prostaglandins via Cox1. Based on these findings we postulate that the stress
neuropeptide CRF present in the vicinity of tumors (either produced locally by the tumor cells
themselves or by nearby normal cells or secreted from the innervations of surrounding tissues)
may play an important role on breast tumor growth and metastatic capacity, providing a potential
link between stress and tumor progression.
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Introduction
Neuropeptides and their receptors are present in the
tumor microenvironment affecting cancer progression [1-
4]. Neuropeptides are known to be produced either from
the tumor cells themselves or by nearby located non-
tumor cells, such as stroma, immune cells or by innervat-
ing autonomic neurons. Corticotropin-releasing factor
(CRF) is the major hypothalamic mediator of the
response to stress. CRF is also a well-known homeostatic
paracrine modulator in the periphery. CRF peptides and
their receptors are also expressed in several types of
tumors [5-8].
The neuropeptide CRF and its family members Urocortin
(UCN)1, UCN2 and UCN3 act via two receptors, CRF1
and CRF2, subtypes of which are differentially expressed
in the central nervous system (CNS) and a multitude of
peripheral tissues [9,10]. Apart of the well-characterized
role of CRF in the homeostatic response to stress, several
actions in peripheral tissues have also been described. The
CRF system has been implicated in the physiology of the
cardiovascular, reproductive and gastrointestinal systems
[11-13]. Moreover, CRF peptides and their receptors are
also present in the immune system and possess immu-
nomodulatory properties [14-18].
Peptides of the CRF family and their receptors have been
detected in various tumors. Several neuroendocrine
tumor cell lines such as the PC12 pheochromocytoma,
Y79 retinoblastoma, IMR-32 and SH-SY5Y neuroblast-
oma, AtT-20 pituitary carcinoma and NCI-H82 small cell
lung cancer cell lines express CRF and the CRF1 receptor
[19-22]. In addition, epithelial tumors and epithelial
tumor cell lines express CRF receptors. CRF1 receptors
have been detected in the MCF7 breast cancer cell line,
while CRF immunoreactivity has been reported in surgical
breast cancer specimen, suggesting a role for the CRF/CRF-
receptor system in breast cancer [23]. CRF and its recep-
tors are also expressed in human melanomas and in
melanoma cell lines [6,7]. It should be noted here that
CRF is constantly present in the microenvironment of
tumors produced by nearby cells including endothelial
cells [24] and immune cells [14] and by the local neuronal
innervations [25].
A number of reports support both a tumor-promoting and
a tumor-inhibitory effect of CRF peptides. Thus, in the
endometrial adenocarcinoma cell line Ishikawa UCN and
CRF inhibit cell proliferation via CRF1 [5]. UCN was also
shown to inhibit the proliferation of melanoma cells both
in vitro and in vivo, through CRF1 [26]. In the human
breast cancer cell line MCF7, CRF inhibits estrogen-
induced proliferation via CRF1 [23]. Moreover, CRF and
CRF related peptides, sauvagine and UCN, inhibit the pro-
liferation of human HaCaT keratinocytes via CRF1 [27].
In addition, CRF has been found to induce the expression
of Fas ligand and apoptosis in the rat PC12 pheochromo-
cytoma cell line also via CRF1 [28]. In contrast, in the Y79
retinoblastoma cell line CRF suppresses apoptosis via
downregulation of pro-caspase 3 cleavage and activation
[29]. It should be mentioned here that the tumor-promot-
ing properties for CRF can be supported by the fact that
CRF induces Fas ligand production in ovarian cancers, an
effect resulting in cytotoxic T-cell apoptosis and local
immunosuppression [8]. Interestingly, ligands of the
other CRF receptor, the CRF2, have been found to sup-
press tumor growth while the expression of the CRF2-spe-
cific endogenous ligand UCN2 in tumors results in
reduced angiogenesis and suppression of tumor growth
[30].
Even though expression of CRF and its receptors has been
described in different types of cancer cells, the role of
these peptides in tumor growth and metastasis has not
been elucidated. The aim of this work was to study the
role of CRF in breast cancer cell homeostasis, motility and
invasiveness. For this purpose we utilized the MCF7 breast
cancer cell line and found that while CRF affected apopto-
sis it also promoted cell motility and invasiveness, sup-
porting a tumor-promoting role for CRF and CRF1
signals.
Methods
Cell culture
The human breast cancer cell line MCF7 was cultured in
Dulbecco's Modified Eagle Medium (DMEM) supple-
mented with 10% fetal calf serum (FCS) and 1% penicil-
lin/streptomycin (all purchased from Invitrogen, UK), at
37°C in a 5% CO2 humidified atmosphere. Cells were
plated at a concentration of 2 × 105 cells/ml until next day
when they had reached at approximately 80% confluence.
The medium was replaced with serum-free one and cells
where stimulated with CRF (Tocris, UK) at a concentra-
tion of 10-8 M for different time points. Control cells were
treated with the CRF diluent, being 0.1% acetic acid.
When antagonists or inhibitors were used, antagonists
were administered one hour prior to stimulation with the
peptide; a-helical CRF (Sigma, USA) and astressin-2B
(kindly provided by Dr. J. Spiess), antagonists of CRF1
and CRF2 respectively, were used at a concentration of 10-
6 M.
RNA isolation and Reverse Transcription-PCR
Total cellular RNA was isolated using Trizol reagent (Inv-
itrogen, UK). Following reverse transcription (Thermo-
script RT, Invitrogen, UK), 1 μl of the cDNA product was
amplified by PCR (Platinum Taq polymerase, Invitrogen,
UK). The primer sets, previously reported to detect the
respective CRF receptors in human brain specimen [31],
were: CRF1a (272 bp): sense 5'-GGCAGCTAGTGGTTCG-Molecular Cancer 2009, 8:30 http://www.molecular-cancer.com/content/8/1/30
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GCC-3' and antisense 5'-TCGCAGGCACCGGATGCTC-3';
CRF1b: sense 5'-GGCCAGGCTGCACCCATTG-3'; anti-
sense 5'-TCGCAGGCACCGGATGCTC-3'; CRF2a: sense 5'-
ATGGACGCGGCACTGCTCCA-3'; antisense 5'-CACG-
GCCTCTCCACGAGGG-3'. For CRF2b (342 bp) sense 5'-
GGGGCTGGCCAGGGTGTGA-3' and antisense 5'-CACG-
GCCTCTCCACGAGGG-3'. CRF2c (300 bp): sense 5'-
CTGTGCTCAAGCAATCTGCC-3' and antisense 5'-CACG-
GCCTCTCCACGAGGG-3'. Beta-Actin (214 bp): sense 5'-
CCGGCCAGCCAGGTCCAGA-3' and antisense 5'-CAAG-
GCCAACCGCGAGAAGATG-3'. Products were amplified
using the following PCR conditions: denaturation at 95°C
for 45 seconds, annealing at 60°C for 45 seconds, exten-
sion at 72°C for 45 seconds, for a total of 40 cycles. A sam-
ple where no-reverse transcriptase was added during
reverse transcription of the RNA (no RT) and another
where water was added instead of cDNA, were used as
controls. 12 μl of the amplified products were separated
on a 2.5% agarose gel and visualized by ethidium bro-
mide staining using the BioRad Molecular Analyst System
[32].
Quantitative measurement of apoptosis
The APOPercentage apoptosis assay (Biocolor Ltd., Bel-
fast, UK) was used to quantify apoptosis, according to
manufacturer's instructions. Briefly, cells were plated in
flat bottom 96-well plates at a concentration of 15,000
cells/well and the next day medium was replaced by
medium free of serum containing CRF at a concentration
of 10-8 M, for different time points. One hour before the
end of the experiment, 5 μl of the APOPercentage dye was
added to each well for one hour. Cells were then washed
with PBS and lysed in the Dye Release Reagent. The APO-
Percentage Apoptosis Assay's dye stained red the apop-
totic cells undergoing the membrane flip-flop event, when
phosphatidylserine is translocated to the outer leaflet.
Apoptosis was quantified after cell lysis by measuring the
dye incorporated in apoptotic cells at 550 nm (reference
filter 620 m) using an Elisa reader (Biorad, UK).
Quantitative measurement of cell growth
Cell growth was measured using the yellow tetrazolium
MTT assay (Sigma, USA). The yellow tetrazolium MTT is
reduced by metabolically active cells, in part by the action
of dehydrogenases. Briefly, 15,000 cells were plated in 96
well plates and treated with CRF At the end of the incuba-
tion period MTT was added at a concentration of 0.5 mg/
ml and incubated for 3 hours. Cells were then lysed by
adding 0.04 N HCl in isopropanol and absorbance was
measured at 620 nm in an ELISA plate reader (Biorad,
UK).
Wound healing assay
Cells were cultured in 60 mm plates until the surface was
completely covered. A small area was then disrupted and
a group of cells was destroyed or displaced by scratching a
line through the layer with a tip [33]. The culture medium
was replaced with serum free medium and cells were stim-
ulated with 10-8 M CRF. The open gap was then inspected
microscopically (Leica, Germany) over time as the cells
moved in and filled the damaged area. Images were cap-
tured at the beginning and at regular time points during
cell migration and the cell migration was quantified by
measuring the distance with the program Image J http://
rsbweb.nih.gov/ij/ between two certain points on either
side of the gap. For proper statistical evaluation, at least
three measurements at different points were performed at
each image.
Cell Invasion Assay
The assay was performed in a 96 well invasion plate based
on the Boyden chamber principle. The bottom of each
well contained an 8 μm pore size polycarbonate mem-
brane coated with a thin layer of Extracellular Matrix
(ECM) through which invasive cells migrate to the bot-
tom of the membrane. Invaded cells were dissociated,
lysed and quantified by fluorometric analysis using SYBR
green, according to the manufacturer's instructions
(Chemicon, USA).
Evaluation of actin reorganization by Confocal Laser 
Scanning Microscopy
Cells were cultured in 8-well chambers slides (50,000 cells
per well). The next day the culture medium was replaced
with serum free medium and cells were stimulated with
10-8 M CRF for 1, 3 and 6 hours. At the end of each exper-
iment, cells were harvested, transferred to tubes, washed
with PBS and permeabilized by exposure to 3.7% formal-
dehyde for 10 minutes. Cells were then incubated with
acetone for 4 minutes at room temperature, washed with
PBS and incubated with 1.5% FCS. Finally, rhodamine-
phalloidin was added to the cells at 1:100 dilution in PBS/
FCS 1.5% for 30 min in the dark. Subsequently, cells were
washed with PBS, analyzed with a confocal laser-scanning
module (Leica Lasertechnik, Heidelberg Germany) and
images were assessed with the respective software.
Measurement of monomeric (G) and polymeric (F) actin by 
Triton X-100 fractionation
The Triton X-100 soluble G-actin and insoluble F-actin-
containing fractions of cells exposed to CRF at 10-8 M in
serum free medium for 3 and 6 hours were prepared as
previously described [34]. The quantification of actin was
performed by reference to a standard curve, prepared from
muscle actin [34]. The G- and total actin contents were
related to the total protein content. Protein concentra-
tions were measured with a commercially available kit
(Bio-Rad, UK). A decrease of the triton-soluble (G) to
total actin ratio [triton-insoluble (F) + triton-soluble (G)]
is indicative of actin polymerization.Molecular Cancer 2009, 8:30 http://www.molecular-cancer.com/content/8/1/30
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Measurment of FAK phosphorylation (Confocal Laser 
Scanning Microscopy)
Cells were cultured in 8-well chambers slides (50,000 cells
per well). The next day the culture medium was replaced
with serum free medium and cells were stimulated with
10-8 M CRF for 3 hours. Cells were harvested, washed with
PBS containing NaF and PMSF and incubated with PFA
4% for 10 min. Cells were then washed with PBS and
0.1% Triton X-100 was added for 15 minutes. Then, cells
were incubated overnight with a monoclonal antibody
against the phosphorylated form of FAK (Cell signaling,
USA). Finally, cells were washed with PBS, stained with
secondary anti-mouse Ig FITC-conjugated antibody raised
in goat, for 1 hour and photographed with a Confocal
Laser Scanning Microscope.
Measurement of total prostaglandin production
2 × 105 cells were plated in 24 well plates and stimulated
with CRF 10-8 for different time points. The supernatants
of the cells were collected and stored at -80°C until ana-
lyzed. The production of total prostaglandins was meas-
ured by the Prostaglandin Screening EIA Kit (Cayman,
USA) according to the manufacturer's instructions. The
assay is based on the competition between PGs and a PG-
acetylcholinesterase conjugate for a limited amount of PG
antiserum.
Western blotting analysis
Western blot analysis of proteins for the detection of tubu-
lin (Chemicon, USA), Cox-1 (Chemicon, USA) and Cox-
2 (Santa Cruz, California, USA) was performed as previ-
ously described [28]. Briefly, protein content in the lysates
was measured by Bradford Assay. SDS-PAGE sample load-
ing buffer was added in 10 μg of protein from each lysate
and electrophoresed through a 12% SDS polyacrylamide
gel. Protein was transferred to nitrocellulose membranes,
using an LKB electroblot transfer system (LKB, Bromma,
Sweden). To detect protein levels, membranes were incu-
bated with the appropriate antibodies and then exposed
to Kodak X-omat AR films. A PC-based Image Analysis
was used to quantify the intensity of each band (Image
Analysis INC., Ontario, Canada).
Statistical analysis
All values were expressed as the average ± Standard Error
of data obtained from at least three independent experi-
ments. Comparison between groups was made using the
ANOVA test (single factor) and p < 0.05 was the signifi-
cance level.
Results
1. Expression of CRF receptor subtypes in MCF7 cells
To confirm that any biological effect of CRF in MCF7 cells
occurred via the characterized CRF receptors we investi-
gated the expression of different CRF receptor subtypes.
Expression of CRF1 has been previously reported in MCF7
cells [23]. RNA from MCF7 cells was analyzed for the
expression of CRF1a, CRF1b, CRF2a and CRF2c receptor
subtypes by RT-PCR. Among these four subtypes, CRF1a
mRNA was expressed in high levels while CRF2c mRNA
was present at very low levels (Figure 1). The mRNAs of
CRF1b, CRF2a were detected in human hippocampus but
were not detected in MCF7 cells (Figure 1).
2. CRF affects apoptosis of MCF7 cells in a time 
dependent-manner
Evasion of apoptosis is a hallmark of cancer cells and is
frequently associated with proliferation and invasiveness
[35-38]. It has been previously reported that CRF has anti-
proliferative effects on cancer cell lines such as Ishikawa
endometrial carcinoma cells and in MCF7 stimulated by
estrogens [5,23]. Herein we confirmed that CRF sup-
presses MCF7 cell proliferation (Figure 2A) and deter-
mined its effect on apoptosis by measuring the exposure
of phosphatidyl-serine on the cell membrane. MCF7 were
treated with CRF at a concentration of 10-8 M for 24, 48,
and 72 hours and apoptosis was quantified. Control cells
were treated with vehicle (0.1% acetic acid). CRF stimula-
tion significantly protected MCF7 cells from serum depri-
vation-induced apoptosis becoming evident 48 hours
following stimulation (Figure 2B). At later time points
apoptosis appeared increased, suggesting a biphasic effect
of CRF on apoptosis.
3. CRF promotes the motility of MCF7 cells
Increase in cell motility has an impact on the metastatic
potential of cancer cells. We, therefore, tested whether
CRF could increase motility of MCF7 cells, a cell line with
low metastatic potential. To this end we performed a
wound healing assay in MCF7 cells, in which a line was
formed by scratching the cell monolayer with a tip [33]. In
this model the gap is mainly covered by cells that move to
close it rather than cells that proliferate, at least at the early
time points when cells do not have enough time to prolif-
erate. At the 24 hour time point the result is a combina-
tion of proliferation and motility. The size of the gap was
measured at different time points following stimulation
using specialized software. Cells were treated with CRF at
time 0 and were compared to vehicle only-treated cells at
for the same period. Results are presented as % of the dis-
tance that remained open at that particular time point
(Figure 3). Hence, at 12 hours 75.08 ± 1.57% of the initial
gap was still open in control, vehicle treated cells, while
56.93 ± 1.17% of the gap was still open in CRF-treated
cells. At 24 hours 55.42 ± 0.65% was still open in control
cells while only 40.75 ± 0.35% of the gap was still uncov-
ered in CRF-treated cells, suggesting that CRF promoted
their motility. Given the fact that CRF reduced cell prolif-
eration and apoptosis was not evident at 24 hours follow-
ing stimulation (Figure 2), the results suggest that CRFMolecular Cancer 2009, 8:30 http://www.molecular-cancer.com/content/8/1/30
Page 5 of 12
(page number not for citation purposes)
stimulated motility that resulted in faster closure of the
gap. The histograms represent the average of four inde-
pendent experiments.
4. CRF induced MCF7 cell invasion through extracellular 
matrix
Invasion through the extracellular matrix (ECM) is a pre-
requisite for tumor metastasis. Since we found that CRF
increased cell motility we further investigated whether it
promoted invasiveness through extracellular matrix.
MCF7 cells were plated on an ECM layer on a Boyden
Chamber in the presence or absence of CRF and migration
of cells through ECM was evaluated. As shown in Figure 4,
incubation of MCF7 with CRF augmented the invasion of
the cells through ECM. Moreover, the CRF1 antagonist, a-
helical CRF abrogated the effect of CRF, while the CRF2
antagonist asstressin-2B had no effect (Figure 4).
5. CRF promoted actin cytoskeleton reorganization in 
MCF7 cells
To determine the potential mechanism involved in CRF-
induced motility and invasiveness we examined the effect
of CRF on actin polymerization dynamics. Actin a major
cytoskeletal component in eukaryotic cells occurs in two
forms, the globular or G-actin, which polymerizes into the
filamentous or F-actin. Filamentous actin is the major
component of microfilaments, present in filipodia and
lamellipodia, which are reported to facilitate cell migra-
tion [39]. In order to assess the role of CRF on cytoskeletal
actin reorganization, we stained MCF7 cells stimulated
with CRF or vehicle (0.1% acetic acid) for different time
points with rhodamine-phalloidin that binds specifically
to polymerized actin and visualized cells by confocal
microscopy, evaluating actin filament structure and fluo-
rescence intensity. As shown in Figure 5A, CRF induced
alterations in actin cytoskeleton morphology, indicating
changes in the polymerization dynamics of this protein.
To quantify the extent of actin polymerization that
occurred in the presence of CRF we analyzed the amount
of monomeric G actin and compared it to the expression
of total actin (monomeric G and polymeric F) providing
the ratio between the two forms as previously reported
[33,40,41]. Three hours following CRF stimulation the G/
total actin ratio was significantly reduced, suggesting actin
CRF1a and CRF2c are expressed in MCF7 cells as detected by RT-PCR Figure 1
CRF1a and CRF2c are expressed in MCF7 cells as detected by RT-PCR. Total RNA was isolated from MCF7 cells 
and the expression of CRF receptors subtypes CRF1a, CRF1b, CRF2a and CRF2c were detected by semi-quantitative RT-PCR. 
The levels of beta Actin were also measured as a normalization control. Results are representative of three independent 
experiments.Molecular Cancer 2009, 8:30 http://www.molecular-cancer.com/content/8/1/30
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CRF affected proliferation and apoptosis of MCF7 cells in a time dependent manner Figure 2
CRF affected proliferation and apoptosis of MCF7 cells in a time dependent manner. Cells were stimulated with 
10-8 M CRF or vehicle (control) for 24, 48, and 72 hours, and cell growth was measured using the MTT assay (A); apoptosis 
was measured by the ApoPercentage Assay (B). CRF significantly suppressed proliferation at all time points tested and apopto-
sis 48 hours after CRF stimulation. Data are expressed as % of control (unstimulated cells). Results represent the average of 4 
independent experiments where each condition was assayed in triplicate. *p < 0.05; **p < 0.01 compared to control cells at the 
same time point.
CRF induces the motility of MCF7 in a wound healing assay Figure 3
CRF induces the motility of MCF7 in a wound healing assay. MCF7 cells were stimulated with 10-8 M CRF or vehicle 
(control) and photographed at 0, 6, 12 and 24 hours after disruption of a small area of the cell layer. The remigration of the 
cells was quantified by measuring the distance at 3 at least different positions on each image with the program Image J, and 
expressed the distance as % of the average. Results represent the average of three independent experiments. *p < 0.05; **p < 
0.01 compared to control cells at the same time point.Molecular Cancer 2009, 8:30 http://www.molecular-cancer.com/content/8/1/30
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polymerization and formation of actin microfilaments
(Figure 5B). Six hours later new monomeric actin was pro-
duced restoring the ratio of monomeric versus polymeric
to the original state but with overall higher expression of
actin, as indicated in Figure 5A.
FAK activation by phosphorylation is the first element,
which may transmit extracellular signals to downstream
signaling proteins, leading to actin reorganization [40,42-
44] and is implicated in cell migration [33,41]. We, there-
fore, examined the effect of CRF on FAK phosphorylation
in MCF7 cells. As shown in Figure 6, the phosphorylation
of FAK was significantly increased in CRF treated MCF7
cells compared to vehicle-treated cells, indicating that it
may also affect MCF7 cell invasiveness.
6. CRF increases prostaglandin production in MCF7 cells 
via Cox-1
Cyclooxygenases (Cox), the enzymes that convert arachi-
donic acid into prostaglandins, have been causally linked
to breast cancer cell proliferation, motility and invasive-
ness [45-48], thus the effect of CRF in prostaglandin pro-
duction and Cox expression was investigated. We
measured total prostaglandin production in supernatants
of MCF7 cells stimulated with CRF by ELISA and found
that CRF induced prostaglandin production in MCF7 cells
(Figure 7A). CRF did not induce PGE2 production in
MCF7 cells as measured by ELISA (data not shown).
Indeed, COX-2 was not induced by CRF in this cell type
(Figure 7B). In contrast, CRF induced COX-1 expression
in a time-dependent manner, suggesting that COX-1
mediates CRF-induced prostaglandin production (Figure
7C).
Discussion
Breast cancer growth is affected by several autocrine and
paracrine factors that regulate tumor cell proliferation,
apoptosis and metastatic potential. CRF is the major
hypothalamic stress-induced neuropeptide but is also
found in peripheral tissues. The aim of the study was to
define the potential effect of CRF on breast cancer cell pro-
liferation, apoptosis and metastatic potential.
We first investigated the expression of CRF receptors in
MCF7 cells to confirm that the cells are responsive to CRF.
In a previous report CRF1 receptor was detected in MCF7
cells [23]. In the present study we found that the CRF1a
isoform was expressed in these cells and CRF2c was also
present but at very low levels, indicating that the major
mediator of CRF actions in MCF7 cells is CRF1 receptor.
Indeed, inhibition of CRF2 receptors had no effect at least
in the induction of cell invasion by CRF. These observa-
tions warrant further analysis of the CRF receptor system
in primary breast cancer tissues that will support the sig-
nificance of these receptors in breast cancer.
Earlier studies had shown that CRF suppressed breast can-
cer cell proliferation while it promoted proliferation in
melanoma cells [6]. Our studies confirmed the suppres-
sive effect of CRF on MCF7 proliferation. We further
investigated the role of CRF on MCF7 cell apoptosis and
found that CRF inhibited apoptosis. The effect of CRF on
apoptosis varies depending on the cell type and the time
detected. Thus, in PC12 rat pheochromocytoma cells CRF
promoted apoptosis [28] while in neuroblastoma [29]
and in melanoma cells it inhibited apoptosis [26]. An ear-
lier study in MCF7 cells showed no effect of CRF on apop-
tosis using a less sensitive method, this of visualizing
fragmented DNA [23]. Differences between cell types may
be attributed to different factors that the cells may pro-
duce; i.e in Y79 neuroblastoma cells CRF inhibited cas-
pase 3 activity [29], while PC12 cells undergo apoptosis in
response to CRF due to production of FasL [28], which is
not expressed in MCF7 cells.
The fact that CRF affected apoptosis and at the same time
it inhibited cell proliferation may indicate changes in the
cellular physiology that could contribute to a metastatic
phenotype. Reduced cell proliferation, at least temporary,
is required for cells to reorganize their cytoskeleton and
promote motility. Indeed, CRF induced motility in MCF7
cells as demonstrated by a wound-healing assay. Cell
motility is facilitated by cytoskeletal rearrangements that
are characterized by actin polymerization. Our results
indicated that CRF promoted polymerization of actin as
CRF enhances the invasion of MCF7 through ECM via CRF1 Figure 4
CRF enhances the invasion of MCF7 through ECM via 
CRF1. MCF7 cells were stimulated with 10-8 M CRF or vehi-
cle (control) and the invasion assay was performed according 
to the manufacturer's instructions. CRF augmented the inva-
sion of the cells through the ECM. Pretreatment with the 
CRF1 antagonist (10-6 M) abrogated the effect of CRF. 
Results represent the average of two independent experi-
ments where each condition was assayed in triplicate. **p < 
0.01 compared to untreated controls; #p < 0.05 compared 
to CRF-treated samples.Molecular Cancer 2009, 8:30 http://www.molecular-cancer.com/content/8/1/30
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determined by measuring the ratio of the monomeric ver-
sus the polymeric actin, as well as visualizing polymerized
actin by immunofluorescence using confocal laser scan-
ning microscopy. Increased actin polymerization is asso-
ciated with dynamic changes in cytoskeletal structures
that allow cells to migrate and metastasize [49]. Focal
Adhesion Kinase is a cytoskeleton associated kinase that is
activated by phosphorylation and mediates signals to pro-
mote cell adhesion and migration [50]. FAK also seems to
play a role in tumor development since it has been shown
that primary human cancer cells or cell lines overexpress
the protein as well as its phosphorylated form [51,52]. In
particular, FAK was found to overexpressed and to be
highly activated in tumorigenic DU145 and PC-3 cells as
well as in prostate cancer tissues from patients with metas-
tasis [52,53] whereas in LNCaP cells that have a lower
tumorigenic ability FAK was observed to be much lower
[44,52]. We found that CRF promoted phosphorylation
of FAK providing a potential mechanism for the actin
reorganization and increased migration observed in
response to CRF. It is, thus, likely that CRF initiates signals
that promote cytoskeletal changes resulting in cell adhe-
sion and migration by activating pathways that involve
FAK phosphorylation.
The metastatic process requires that cells do not only have
increased motility but they should also obtain the capac-
ity to migrate through the ECM. For this purpose we
examined the effect of CRF to promote invasion through
ECM in MCF7 cells that have low metastatic potential.
A. CRF affects actin cytoskeleton Figure 5
A. CRF affects actin cytoskeleton. MCF7 cells were plated in chamber-slides, stimulated with 10-8 M CRF or vehicle (con-
trol) for 1, 3 and 6 hours and stained with rhodamine-phalloidine. Fluorescence was measured by confocal microscopy. Results 
are representative of three independent experiments.B. CRF induces actin polymerization. MCF7 cells were stimulated with CRF 
(10-8 M) or vehicle (control) for 3 and 6 hours. Cells were harvested and the two fractions, soluble and insoluble, containing 
the monomeric (globular) and the polymerized (filamentous) actin respectively were isolated and analyzed by western blotting 
using antibody against actin. The relative proportion of F- and G-actin was determined by the concentration of monomeric (G) 
and total (F+G) actin and the result is presented as the G/(F+G) ratio induced by CRF compared to control; p < 0,01. Results 
represent the average of five independent experiments.Molecular Cancer 2009, 8:30 http://www.molecular-cancer.com/content/8/1/30
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CRF induces the phosphorylation of FAK Figure 6
CRF induces the phosphorylation of FAK. MCF7 cells were treated with CRF (10-8 M) or vehicle (control) for 3 hours, 
stained with phospho-FAK antibody and analyzed with confocal microscopy. Result is representative of three independent 
experiments.
CRF induces the expression of Cox-1 and the production of prostaglandins Figure 7
CRF induces the expression of Cox-1 and the production of prostaglandins. A. MCF7 cells were treated with CRF 
(10-8 M) or vehicle (control) for 6 and16 hours and total prostaglandin production in the supernatant was measured by ELISA; 
***p < 0.001; Results represent the average of three independent experiments. B. MCF7 cells were treated with CRF (10-8 M) 
for 3, 6 and 24 hours and Cox-2 was measured by western blot. C. MCF7 cells were treated with CRF (10-8 M) for 6, 12 and 
24 hours and Cox-1 was measured by western blot. Results are representative of three independent experiments.Molecular Cancer 2009, 8:30 http://www.molecular-cancer.com/content/8/1/30
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Indeed, treatment with CRF increased the invasiveness of
MCF7 cells through ECM. Invasiveness, through ECM was
measured using a boyden chamber assay, in which cells
were plated on an ECM coated surface. Hence, cells
should not only obtain the capability of migration, they
should also be able to destroy the ECM in order to pene-
trate tissue barriers and metastasize. MCF7 breast cancer
cells obtain this capability by expressing matrix metallo-
proteinases [54].
Cyclooxygenase activation and prostaglandin production
has also been associated with increase in metastasis
[47,55,56]. Inhibition of Cox-2 is associated with
decrease in tumor growth and invasiveness [56,57]. Cox-
1, an otherwise constitutively expressed Cox isoform, is
also upregulated in breast cancer and is associated with
increased prostaglandins and metastatic potential
[56,58]. The primary Cox isoform expressed in MCF7 cells
is Cox-1 [59]. We, therefore, examined the production of
prostaglandins in response to CRF in MCF7 cells. CRF
induced prostaglandin production but it did not alter
PGE2 levels. In contrast, CRF increased the levels of Cox-
1 suggesting that Cox-1-derived prostaglandins may
mediate the effect of CRF on MCF7 cell invasiveness.
Indeed, several reports have indicated that selective inhi-
bition of Cox-1 results in inhibition of tumor growth and
metastasis [56,58].
Conclusion
In conclusion, CRF appears to positively affect tumor
growth by inhibiting apoptosis and promoting cell migra-
tion and invasiveness. Our results provide a potential link
between stress and tumor growth, suggesting that CRF
secreted from autonomic neurons innervating peripheral
tissues [25] may contribute to breast cancer metastasis.
Given recent findings for the anti-tumor properties of
CRF2 agonists [30] and the lack of CRF2 expression on
breast cancer cells one may suggest that inhibition of
CRF1 and activation of CRF2 may successfully inhibit
tumor growth.
Abbreviations
CRF: Corticotropin Releasing Factor; CRF1, CRF2: Corti-
cotropin Releasing Factor receptor 1, or receptor 2; FAK:
Focal Adhesion Kinase; UCN: Urocortin; COX: Cyclooxy-
genase; ECM: Extracellular Cell Matrix; PG: Prostaglandin;
PGE2: Prostaglandin E2.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
AA participated in the molecular and cell biology studies
and drafted the manuscript. ED participated in the
immunofluorescence and confocal microscopy analyses
and co-ordination of the study. MV participated in the
analysis of CRF receptor expression, cell proliferation and
apoptosis, data evaluation, co-ordination of the study and
manuscript preparation. EK participated in the molecular
and cell biology studies and data analysis. OR participated
in the detection of CRF receptors. EA participated in the
analysis of prostaglandin production and cyclooxygenase
expression. CS and ANM participated in the design of the
study and drafting of the manuscript. CT conceived of the
study, participated in its design and drafted the manu-
script. All authors read and approved the final manu-
script.
Acknowledgements
This work was partly supported from the Association for International 
Cancer Research (AICR07-0072) to CT and from the Hellenic Secretariat 
for Research and Technology (ΠENEΔ 03EΔ372) to ANM.
References
1. Miao Y, Quinn TP: Alpha-melanocyte stimulating hormone
peptide-targeted melanoma imaging.  Front Biosci 2007,
12:4514-4524.
2. Gudermann T, Roelle S: Calcium-dependent growth regulation
of small cell lung cancer cells by neuropeptides.  Endocr Relat
Cancer 2006, 13:1069-1084.
3. Carraway RE, Plona AM: Involvement of neurotensin in cancer
growth: evidence, mechanisms and development of diagnos-
tic tools.  Peptides 2006, 27:2445-2460.
4. Muller JM, Philippe M, Chevrier L, Heraud C, Alleaume C, Chadeneau
C: The VIP-receptor system in neuroblastoma cells.  Regul
Pept 2006, 137:34-41.
5. Graziani G, Tentori L, Portarena I, Barbarino M, Tringali G, Pozzoli G,
Navarra P: CRH inhibits cell growth of human endometrial
adenocarcinoma cells via CRH-receptor 1-mediated activa-
tion of cAMP-PKA pathway.  Endocrinology 2002, 143:807-813.
6. Sato H, Nagashima Y, Chrousos GP, Ichihashi M, Funasak Y: The
expression of corticotropin-releasing hormone in
melanoma.  Pigment Cell Res 2002, 15:98-103.
7. Funasaka Y, Sato H, Chakraborty AK, Ohashi A, Chrousos GP, Ichi-
hashi M: Expression of proopiomelanocortin, corticotropin-
releasing hormone (CRH), and CRH receptor in melanoma
cells, nevus cells, and normal human melanocytes.  J Investig
Dermatol Symp Proc 1999, 4:105-109.
8. Minas V, Rolaki A, Kalantaridou SN, Sidiropoulos J, Mitrou S, Petsas
G, Jeschke U, Paraskevaidis EA, Fountzilas G, Chrousos GP, Pavlidis
N, Makrigiannakis A: Intratumoral CRH modulates immuno-
escape of ovarian cancer cells through FasL regulation.  Br J
Cancer 2007, 97:637-645.
9. Boorse GC, Denver RJ: Widespread tissue distribution and
diverse functions of corticotropin-releasing factor and
related peptides.  Gen Comp Endocrinol 2006, 146:9-18.
10. Dautzenberg FM, Hauger RL: The CRF peptide family and their
receptors: yet more partners discovered.  Trends Pharmacol Sci
2002, 23:71-77.
11. Brar BK, Jonassen AK, Stephanou A, Santilli G, Railson J, Knight RA,
Yellon DM, Latchman DS: Urocortin protects against ischemic
and reperfusion injury via a MAPK-dependent pathway.  J Biol
Chem 2000, 275:8508-8514.
12. Makrigiannakis A, Zoumakis E, Kalantaridou S, Mitsiades N, Margioris
A, Chrousos GP, Gravanis A: Corticotropin-releasing hormone
(CRH) and immunotolerance of the fetus.  Biochem Pharmacol
2003, 65:917-921.
13. Chatzaki E, Charalampopoulos I, Leontidis C, Mouzas IA, Tzardi M,
Tsatsanis C, Margioris AN, Gravanis A: Urocortin in human gas-
tric mucosa: relationship to inflammatory activity.  J Clin Endo-
crinol Metab 2003, 88:478-483.
14. Baigent SM: Peripheral corticotropin-releasing hormone and
urocortin in the control of the immune response.  Peptides
2001, 22:809-820.Molecular Cancer 2009, 8:30 http://www.molecular-cancer.com/content/8/1/30
Page 11 of 12
(page number not for citation purposes)
15. Agnello D, Bertini R, Sacco S, Meazza C, Villa P, Ghezzi P: Corticos-
teroid-independent inhibition of tumor necrosis factor pro-
duction by the neuropeptide urocortin.  Am J Physiol 1998,
275:E757-762.
16. McEvoy AN, Bresnihan B, FitzGerald O, Murphy EP: Corticotropin-
releasing hormone signaling in synovial tissue from patients
with early inflammatory arthritis is mediated by the type 1
alpha corticotropin-releasing hormone receptor.  Arthritis
Rheum 2001, 44:1761-1767.
17. Sashinami H, Kageyama K, Suda T, Nakane A: Urocortin 2 sup-
presses host resistance to Listeria monocytogenes infection
via up-regulation of interleukin-10.  Endocrinology 2005,
146:5003-5011.
18. Tsatsanis C, Androulidaki A, Alissafi T, Charalampopoulos I, Dermit-
zaki E, Roger T, Gravanis A, Margioris AN: Corticotropin-releas-
ing factor and the urocortins induce the expression of TLR4
in macrophages via activation of the transcription factors
PU.1 and AP-1.  J Immunol 2006, 176:1869-1877.
19. Wang J, Li S: Corticotropin-releasing  factor family and its
receptors: tumor therapeutic targets?  Biochem Biophys Res Com-
mun 2007, 362:785-788.
20. Gutknecht E, Hauger RL, Linden I Van der, Vauquelin G, Dautzenberg
FM: Expression, binding, and signaling properties of CRF2(a)
receptors endogenously expressed in human retinoblastoma
Y79 cells: passage-dependent regulation of functional recep-
tors.  J Neurochem 2008, 104:926-936.
21. Dieterich KD, DeSouza EB: Functional corticotropin-releasing
factor receptors in human neuroblastoma cells.  Brain Res
1996, 733:113-118.
22. Schoeffter P, Feuerbach D, Bobirnac I, Gazi L, Longato R: Func-
tional, endogenously expressed corticotropin-releasing fac-
tor receptor type 1 (CRF1) and CRF1 receptor mRNA
expression in human neuroblastoma SH-SY5Y cells.  Fundam
Clin Pharmacol 1999, 13:484-489.
23. Graziani G, Tentori L, Muzi A, Vergati M, Tringali G, Pozzoli G, Nav-
arra P: Evidence that corticotropin-releasing hormone inhib-
its cell growth of human breast cancer cells via the activation
of CRH-R1 receptor subtype.  Mol Cell Endocrinol 2007,
264:44-49.
24. Arbiser JL, Karalis K, Viswanathan A, Koike C, Anand-Apte B, Flynn
E, Zetter B, Majzoub JA: Corticotropin-releasing hormone stim-
ulates angiogenesis and epithelial tumor growth in the skin.
J Invest Dermatol 1999, 113:838-842.
25. Bale TL, Vale WW: CRF and CRF receptors: role in stress
responsivity and other behaviors.  Annu Rev Pharmacol Toxicol
2004, 44:525-557.
26. Carlson KW, Nawy SS, Wei ET, Sadee W, Filov VA, Rezsova VV, Slo-
minski A, Quillan JM: Inhibition of mouse melanoma cell prolif-
eration by corticotropin-releasing hormone and its analogs.
Anticancer Res 2001, 21:1173-1179.
27. Slominski AT, Roloff B, Zbytek B, Wei ET, Fechner K, Curry J, Worts-
man J: Corticotropin releasing hormone and related peptides
can act as bioregulatory factors in human keratinocytes.  In
Vitro Cell Dev Biol Anim 2000, 36:211-216.
28. Dermitzaki E, Tsatsanis C, Gravanis A, Margioris AN: Corticotro-
pin-releasing hormone induces Fas ligand production and
apoptosis in PC12 cells via activation of p38 mitogen-acti-
vated protein kinase.  J Biol Chem 2002, 277:12280-12287.
29. Radulovic M, Hippel C, Spiess J: Corticotropin-releasing factor
(CRF) rapidly suppresses apoptosis by acting upstream of
the activation of caspases.  J Neurochem 2003, 84:1074-1085.
30. Hao Z, Huang Y, Cleman J, Jovin IS, Vale WW, Bale TL, Giordano FJ:
Urocortin2 inhibits tumor growth via effects on vasculariza-
tion and cell proliferation.  Proc Natl Acad Sci USA 2008,
105:3939-3944.
31. Cao J, Papadopoulou N, Kempuraj D, Boucher WS, Sugimoto K,
Cetrulo CL, Theoharides TC: Human mast cells express cortico-
tropin-releasing hormone (CRH) receptors and CRH leads
to selective secretion of vascular endothelial growth factor.
J Immunol 2005, 174:7665-7675.
32. Christoforidou AV, Papadaki HA, Margioris AN, Eliopoulos GD, Tsat-
sanis C: Expression of the Tpl2/Cot oncogene in human T-cell
neoplasias.  Mol Cancer 2004, 3:34.
33. Kallergi G, Agelaki S, Markomanolaki H, Georgoulias V, Stournaras C:
Activation of FAK/PI3K/Rac1 signaling controls actin reor-
ganization and inhibits cell motility in human cancer cells.
Cell Physiol Biochem 2007, 20:977-986.
34. Papakonstanti EA, Stournaras C: Actin cytoskeleton architecture
and signaling in osmosensing.  Methods Enzymol 2007,
428:227-240.
35. Gu JM, Lim SO, Park YM, Jung G: A novel splice variant of occlu-
din deleted in exon 9 and its role in cell apoptosis and inva-
sion.  Febs J 2008, 275:3145-3156.
36. Wang Z, Song W, Aboukameel A, Mohammad M, Wang G, Banerjee
S, Kong D, Wang S, Sarkar FH, Mohammad RM: TW-37, a small-
molecule inhibitor of Bcl-2, inhibits cell growth and invasion
in pancreatic cancer.  Int J Cancer 2008, 123(4):958-66.
37. Kargiotis O, Chetty C, Gondi CS, Tsung AJ, Dinh DH, Gujrati M,
Lakka SS, Kyritsis AP, Rao JS: Adenovirus-mediated transfer of
siRNA against MMP-2 mRNA results in impaired invasion
and tumor-induced angiogenesis, induces apoptosis in vitro
and inhibits tumor growth in vivo in glioblastoma.  Oncogene
2008, 27(35):4830-40.
38. Xiong H, Zhang ZG, Tian XQ, Sun DF, Liang QC, Zhang YJ, Lu R,
Chen YX, Fang JY: Inhibition of JAK1, 2/STAT3 signaling
induces apoptosis, cell cycle arrest, and reduces tumor cell
invasion in colorectal cancer cells.  Neoplasia 2008, 10:287-297.
39. Machesky LM: Lamellipodia and filopodia in metastasis and
invasion.  FEBS Lett 2008, 582:2102-2111.
40. Kallergi G, Tsapara A, Kampa M, Papakonstanti EA, Krasagakis K, Cas-
tanas E, Stournaras C: Distinct signaling pathways regulate dif-
ferential opioid effects on actin cytoskeleton in malignant
MCF7 and nonmalignant MCF12A human breast epithelial
cells.  Exp Cell Res 2003, 288:94-109.
41. Papakonstanti EA, Stournaras C: Cell responses regulated by
early reorganization of actin cytoskeleton.  FEBS Lett 2008,
582:2120-2127.
42. Koukouritaki SB, Gravanis A, Stournaras C: Tyrosine phosphoryla-
tion of focal adhesion kinase and paxillin regulates the sign-
aling mechanism of the rapid nongenomic action of
dexamethasone on actin cytoskeleton.  Mol Med 1999,
5:731-742.
43. Chen HC, Guan JL: Association of focal adhesion kinase with its
potential substrate phosphatidylinositol 3-kinase.  Proc Natl
Acad Sci USA 1994, 91:10148-10152.
44. Papakonstanti EA, Kampa M, Castanas E, Stournaras C: A rapid,
nongenomic, signaling pathway regulates the actin reorgan-
ization induced by activation of membrane testosterone
receptors.  Mol Endocrinol 2003, 17:870-881.
45. Hiraga T, Myoui A, Choi ME, Yoshikawa H, Yoneda T: Stimulation
of cyclooxygenase-2 expression by bone-derived transform-
ing growth factor-beta enhances bone metastases in breast
cancer.  Cancer Res 2006, 66:2067-2073.
46. Timoshenko AV, Xu G, Chakrabarti S, Lala PK, Chakraborty C: Role
of prostaglandin E2 receptors in migration of murine and
human breast cancer cells.  Exp Cell Res 2003, 289:265-274.
47. Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN: Signalling
networks regulating cyclooxygenase-2.  Int J Biochem Cell Biol
2006, 38:1654-1661.
48. Basu GD, Liang WS, Stephan DA, Wegener LT, Conley CR, Pockaj
BA, Mukherjee P: A novel role for cyclooxygenase-2 in regulat-
ing vascular channel formation by human breast cancer cells.
Breast Cancer Res 2006, 8:R69.
49. Olson MF, Sahai E: The actin cytoskeleton in cancer cell motil-
ity.  Clin Exp Metastasis.  2009, 28(4):273-287.
50. Basson MD: An intracellular signal pathway that regulates
cancer cell adhesion in response to extracellular forces.  Can-
cer Res 2008, 68:2-4.
51. Jones RJ, Brunton VG, Frame MC: Adhesion-linked kinases in
cancer; emphasis on src, focal adhesion kinase and PI 3-
kinase.  Eur J Cancer 2000, 36:1595-1606.
52. Tremblay L, Hauck W, Aprikian AG, Begin LR, Chapdelaine A, Chev-
alier S: Focal adhesion kinase (pp125FAK) expression, activa-
tion and association with paxillin and p50CSK in human
metastatic prostate carcinoma.  Int J Cancer 1996, 68:164-171.
53. Papadopoulou N, Charalampopoulos I, Alevizopoulos K, Gravanis A,
Stournaras C: Rho/ROCK/actin signaling regulates membrane
androgen receptor induced apoptosis in prostate cancer
cells.  Exp Cell Res 2008, 314:3162-3174.
54. Milde-Langosch K, Roder H, Andritzky B, Aslan B, Hemminger G,
Brinkmann A, Bamberger CM, Loning T, Bamberger AM: The role ofPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Molecular Cancer 2009, 8:30 http://www.molecular-cancer.com/content/8/1/30
Page 12 of 12
(page number not for citation purposes)
the AP-1 transcription factors c-Fos, FosB, Fra-1 and Fra-2 in
the invasion process of mammary carcinomas.  Breast Cancer
Res Treat 2004, 86:139-152.
55. Surowiak P, Materna V, Matkowski R, Szczuraszek K, Kornafel J, Woj-
nar A, Pudelko M, Dietel M, Denkert C, Zabel M, Lage H: Relation-
ship between the expression of cyclooxygenase 2 and MDR1/
P-glycoprotein in invasive breast cancers and their prognos-
tic significance.  Breast Cancer Res 2005, 7:R862-870.
56. Kundu N, Fulton AM: Selective cyclooxygenase (COX)-1 or
COX-2 inhibitors control metastatic disease in a murine
model of breast cancer.  Cancer Res 2002, 62:2343-2346.
57. Barnes NL, Warnberg F, Farnie G, White D, Jiang W, Anderson E,
Bundred NJ: Cyclooxygenase-2 inhibition: effects on tumour
growth, cell cycling and lymphangiogenesis in a xenograft
model of breast cancer.  Br J Cancer 2007, 96:575-582.
58. Connolly EM, Harmey JH, O'Grady T, Foley D, Roche-Nagle G, Kay
E, Bouchier-Hayes DJ: Cyclo-oxygenase inhibition reduces
tumour growth and metastasis in an orthotopic model of
breast cancer.  Br J Cancer 2002, 87:231-237.
59. Liu XH, Rose DP: Differential expression and regulation of
cyclooxygenase-1 and -2 in two human breast cancer cell
lines.  Cancer Res 1996, 56:5125-5127.